Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 16, 2016 - Issue 1
Submit an article Journal homepage
620
Views
20
CrossRef citations to date
0
Altmetric
Reviews

Cost-effectiveness of adherence-enhancing interventions: a systematic review

Tzahit Simon-TuvalDepartment of Health Systems Management, Guilford-Glazer Faculty of Business and Management and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, IsraelCorrespondence[email protected]
,
Peter J. NeumannCenter for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA
&
Dan GreenbergDepartment of Health Systems Management, Guilford-Glazer Faculty of Business and Management and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
Pages 67-84 | Received 15 Nov 2015, Accepted 04 Jan 2016, Published online: 03 Feb 2016

References

• This systematic review included RCTs of interventions intended to enhance patient adherence to prescribed medications. It revealed that only a minority of lowest risk of bias RCTs improved both adherence and clinical outcomes.

  • Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;2:CD000011.
  • van Boven JF, Chavannes NH, van der Molen T, et al. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med. 2014;108(1):103–113.
  • Chaiyachati KH, Ogbuoji O, Price M, et al. Interventions to improve adherence to antiretroviral therapy: a rapid systematic review. Aids. 2014;28(Suppl 2):S187–204.
  • Mbuagbaw L, Sivaramalingam B, Navarro T, et al. Interventions for enhancing adherence to antiretroviral therapy (ART): a systematic review of high quality studies. AIDS Patient Care STDS. 2015;29(5):248–266.
  • Al-Aqeel S, Al-Sabhan J. Strategies for improving adherence to antiepileptic drug treatment in patients with epilepsy. Cochrane Database Syst Rev. 2011;1:CD008312.
  • Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2010;3:CD004371.
  • Iuga AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy. 2014;7:35–44.

• This review provided extensive discussion on the magnitude of nonadherence to medications and its associated costs in the context of the US health system.

  • IMS Institute for Healthcare Informatics. Avoidable costs in US health care. The $200 billion opportunity from using medicines more responsibly [Internet]. 2013 [cited 2015 Nov 15]. Available from: http://www.imshealth.com/en/thought-leadership/ims-institute/reports/avoidable-costs.
  • Mennini FS, Marcellusi A, von der Schulenburg JM, et al. Cost of poor adherence to anti-hypertensive therapy in five European countries. Eur J Health Econ. 2015;16(1):65–72.
  • Simon-Tuval T, Triki N, Chodick G, et al. The association between adherence to cardiovascular medications and healthcare utilization. Eur J Health Econ. 2015. doi:10.1007/s10198-015-0703-z.
  • Dilla T, Ciudad A, Alvarez M. Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence. 2013;7:275–284.
  • Mathes T, Pieper D, Antoine SL, et al. Cost-effectiveness of adherence interventions for highly active antiretroviral therapy: a systematic review. Int J Technol Assess Health Care. 2013;29(3):227–233.

• This review focuses on the cost-effectiveness of interventions targeted at improving adherence to highly active antiretroviral therapy. It argues that although favorable ICERs were estimated, a definitive conclusion cannot be derived due to limited quality of the methodologies applied.

  • Chapman RH, Kowal SL, Cherry SB, et al. The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications. Value Health. 2010;13(6):685–694.

• This systematic review analyzed the relative cost-effectiveness of various interventions and revealed that reminders, educational materials and a pharmacist/nurse management program, appear to be and should be considered before other interventions.

  • Oberje EJ, De Kinderen RJ, Evers SM, et al. Cost effectiveness of medication adherence-enhancing interventions: a systematic review of trial-based economic evaluations. Pharmacoeconomics. 2013;31(12):1155–1168.

•• A valuable systematic review that examined the cost-effectiveness of RCT-based interventions to improve adherence to medications. The authors evaluated the studies’ quality as modest and reffered to their narrow economic perspectives, thus recommended to apply more comprehensive economic evaluations.

  • Altowaijri A, Phillips CJ, Fitzsimmons D. A systematic review of the clinical and economic effectiveness of clinical pharmacist intervention in secondary prevention of cardiovascular disease. J Manag Care Pharm. 2013;19(5):408–416.
  • Center for the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry [Internet]. (Boston), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center. Available from: www.cearegistry.org.
  • Neumann PJ, Greenberg D, Olchanski NV, et al. Growth and quality of the cost-utility literature, 1976-2001. Value Health. 2005;8(1):3–9.
  • Neumann PJ, Thorat T, Shi J, et al. The changing face of the cost-utility literature, 1990-2012. Value Health. 2015;18(2):271–277.
  • Keeler EB, Robalino DA, Frank JC, et al. Cost-effectiveness of outpatient geriatric assessment with an intervention to increase adherence. Med Care. 1999;37(12):1199–1206.
  • Freedberg KA, Hirschhorn LR, Schackman BR, et al. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S113–8.
  • Zaric GS, Bayoumi AM, Brandeau ML, et al. The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men. Med Decis Making. 2008;28(3):359–376.
  • Van Keulen HM, Bosmans JE, Van Tulder MW, et al. Cost-effectiveness of tailored print communication, telephone motivational interviewing, and a combination of the two: results of an economic evaluation alongside the Vitalum randomized controlled trial. Int J Behav Nutr Phys Act. 2010;7:64.
  • Begh RA, Aveyard P, Upton P, et al. Promoting smoking cessation in Pakistani and Bangladeshi men in the UK: pilot cluster randomised controlled trial of trained community outreach workers. Trials. 2011;12:197.
  • Murphy SM, Edwards RT, Williams N, et al. An evaluation of the effectiveness and cost effectiveness of the National Exercise Referral Scheme in Wales, UK: a randomised controlled trial of a public health policy initiative. J Epidemiol Community Health. 2012;66(8):745–753.
  • Ito K, Shrank WH, Avorn J, et al. Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction. Health Serv Res. 2012;47(6):2097–2117.
  • Herman WH, Edelstein SL, Ratner RE, et al. Effectiveness and cost-effectiveness of diabetes prevention among adherent participants. Am J Manag Care. 2013;19(3):194–202.
  • Patel A, McCrone P, Leese M, et al. Cost-effectiveness of adherence therapy versus health education for people with schizophrenia: randomised controlled trial in four European countries. Cost Eff Resour Alloc. 2013;11(1):12.
  • Plumpton CO, Brown I, Reuber M, et al. Economic evaluation of a behavior-modifying intervention to enhance antiepileptic drug adherence. Epilepsy Behav. 2015;45:180–186.
  • Ladabaum U, Mannalithara A, Jandorf L, et al. Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals. Cancer. 2015;121(7):1088–1097.
  • Wilson FA, Villarreal R, Stimpson JP, et al. Cost-effectiveness analysis of a colonoscopy screening navigator program designed for Hispanic men. J Cancer Educ. 2015;30(2):260–267.
  • Korn P, Patel ST, Heller JA, et al. Why insurers should reimburse for compression stockings in patients with chronic venous stasis. J Vasc Surg. 2002;35(5):950–957.
  • Rosen AB, Hamel MB, Weinstein MC, et al. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005;143(2):89–99.
  • Choudhry NK, Patrick AR, Antman EM, et al. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation. 2008;117(10):1261–1268.
  • Dhalla IA, Smith MA, Choudhry NK, et al. Costs and benefits of free medications after myocardial infarction. Healthc Policy. 2009;5(2):68–86.
  • Ito K, Elkin E, Blinder V, et al. Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer. Cancer. 2013;119(13):2494–2502.
  • Billings ME, Kapur VK. Medicare long-term CPAP coverage policy: a cost-utility analysis. J Clin Sleep Med. 2013;9(10):1023–1029.
  • Ito K, Avorn J, Shrank WH, et al. Long-term cost-effectiveness of providing full coverage for preventive medications after myocardial infarction. Circ Cardiovasc Qual Outcomes. 2015;8(3):252–259.
  • Gordois A, Armour C, Brillant M, et al. Cost-effectiveness analysis of a pharmacy asthma care program in Australia. Dis Manag Health Out. 2007;15(6):387–396.
  • Yu J, Shah BM, Ip EJ, et al. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California. J Manag Care Pharm. 2013;19(2):102–114.
  • Rubio-Valera M, Bosmans J, Fernandez A, et al. Cost-effectiveness of a community pharmacist intervention in patients with depression: a randomized controlled trial (PRODEFAR Study). PLoS One. 2013;8(8):e70588.
  • van Boven JF, Tommelein E, Boussery K, et al. Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis. Respir Res. 2014;15:66.
  • Vegter S, Oosterhof P, Van Boven JF, et al. Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis. J Manag Care Spec Pharm. 2014;20(7):722–732.
  • Twigg MJ, Wright D, Barton GR, et al. The four or more medicines (FOMM) support service: results from an evaluation of a new community pharmacy service aimed at over-65s. Int J Pharm Pract. 2015. doi:10.1111/ijpp.12196.
  • Earnshaw SR, Graham CN, Ettinger B, et al. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin. 2007;23(10):2517–2529.
  • Connolly MP, Nielsen SK, Currie CJ, et al. An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. J Crohns Colitis. 2009;3(1):32–37.
  • Ascher-Svanum H, Furiak NM, Lawson AH, et al. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. J Med Econ. 2012;15(3):531–547.
  • Gaebler JA, Soto-Campos G, Alperin P, et al. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. Vasc Health Risk Manag. 2012;8:255–264.
  • Colombo GL, Di Matteo S, Maggiolo F. Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen. Clinicoecon Outcomes Res. 2013;5:59–68.
  • Connolly MP, Kuyvenhoven JP, Postma MJ, et al. Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing. J Crohns Colitis. 2014;8(5):357–362.
  • Becerra V, Gracia A, Desai K, et al. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. BMJ Open. 2015;5(5):e007111.
  • Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003;115(8):632–641.
  • Brunenberg DE, Wetzels GE, Nelemans PJ, et al. Cost effectiveness of an adherence-improving programme in hypertensive patients. Pharmacoeconomics. 2007;25(3):239–251.
  • McCabe CJ, Goldie SJ, Fisman DN. The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women. PLoS One. 2010;5(4):e10154.
  • Ownby RL, Waldrop-Valverde D, Jacobs RJ, et al. Cost effectiveness of a computer-delivered intervention to improve HIV medication adherence. BMC Med Inform Decis Mak. 2013;13:29.
  • Cronin P, Goodall S, Lockett T, et al. Cost-effectiveness of an advance notification letter to increase colorectal cancer screening. Int J Technol Assess Health Care. 2013;29(3):261–268.
  • Trenaman L, Sadatsafavi M, Almeida F, et al. Exploring the potential cost-effectiveness of patient decision aids for use in adults with obstructive sleep apnea: a case study. Med Decis Making. 2015;35(5):671–682.
  • Majumdar SR, Johnson JA, Lier DA, et al. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial. Osteoporos Int. 2007;18(3):261–270.
  • Gopalappa C, Farnham PG, Hutchinson AB, et al. Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons. J Acquir Immune Defic Syndr. 2012;61(1):99–105.
  • Carrion JA, Gonzalez-Colominas E, Garcia-Retortillo M, et al. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. J Hepatol. 2013;59(5):926–933.
  • Kominski GF, Varon SF, Morisky DE, et al. Costs and cost-effectiveness of adolescent compliance with treatment for latent tuberculosis infection: results from a randomized trial. J Adolesc Health. 2007;40(1):61–68.
  • Babigumira JB, Sethi AK, Smyth KA, et al. Cost effectiveness of facility-based care, home-based care and mobile clinics for provision of antiretroviral therapy in Uganda. Pharmacoeconomics. 2009;27(11):963–973.
  • Rosen AB, Spaulding AB, Greenberg D, et al. Patient adherence: a blind spot in cost-effectiveness analyses? Am J Manag Care. 2009;15(9):626–632.
  • Sabaté E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.

• This comprehensive overview of sources of non-adherence provides the theoretical basis for the design of adherence-enhancing interventions.

  • Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. Jama. 2002;288(14):1775–1779.
  • Ramsey SD, Willke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value Health. 2015;18(2):161–172.
  • Heisler M, Choi H, Rosen AB, et al. Hospitalizations and deaths among adults with cardiovascular disease who underuse medications because of cost: a longitudinal analysis. Med Care. 2010;48(2):87–94.
  • Choudhry NK, Saya UY, Shrank WH, et al. Cost-related medication underuse: prevalence among hospitalized managed care patients. J Hosp Med. 2012;7(2):104–109.
  • Kennedy J, Morgan S. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries. Clin Ther. 2009;31(1):213–219.
  • Kemp A, Roughead E, Preen D, et al. Determinants of self-reported medicine underuse due to cost: a comparison of seven countries. J Health Serv Res Policy. 2010;15(2):106–114.
  • Guessous I, Gaspoz JM, Theler JM, et al. High prevalence of forgoing healthcare for economic reasons in Switzerland: a population-based study in a region with universal health insurance coverage. Prev Med. 2012;55(5):521–527.
  • Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med. 2007;22(6):864–871.
  • Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26(2):w195–203.
  • Fendrick AM, Chernew ME. Value-based insurance design: a “clinically sensitive” approach to preserve quality of care and contain costs. Am J Manag Care. 2006;12(1):18–20.
  • Fendrick AM, Smith DG, Chernew ME, et al. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7(9):861–867.
  • Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171(9):814–822.
  • Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006;332(7543):699–703.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.